CCCC in the 13F filings
C4 Therapeutics Inc · CUSIP 12529R107
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 20
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 1 listed it in both
- Shares listed
- 20,354,509
- combined, among listed positions
- Reported value
- $39m
- combined, at the quarter end
Among the 92 comparable managers: 16 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +13,894,863.
Managers listing CCCC in Q4 2025
20 of 20 holders
Largest increases and reductions, by shares
Increases
- Point72 Asset Management LPnew position · 9,439,328 shares now+9,439,328
- Susquehanna International Group LLPexisting position · 1,775,783 shares now+1,260,346
- Two Sigma Investments LPexisting position · 1,509,603 shares now+674,877
- Jane Street Group LLCexisting position · 874,794 shares now+671,226
- Renaissance Technologies LLCexisting position · 1,602,580 shares now+665,630
Reductions
- Millennium Management LLCexisting position · 1,188,969 shares now-745,256
- Citadel Advisors LLCexisting position · 447,808 shares now-33,641
New positions and exits
New (4)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 1 | $5.5m | n.a. | n.a. |
| Q1 2021 | 1 | $2.0m | n.a. | n.a. |
| Q2 2021 | 1 | $981k | n.a. | n.a. |
| Q4 2021 | 1 | $2.6m | n.a. | n.a. |
| Q1 2022 | 1 | $12m | n.a. | n.a. |
| Q2 2022 | 2 | $3.2m | n.a. | n.a. |
| Q4 2022 | 1 | $338k | n.a. | n.a. |
| Q1 2023 | 2 | $369k | n.a. | n.a. |
| Q2 2023 | 1 | $73k | n.a. | n.a. |
| Q1 2024 | 2 | $401k | 2 | 0 |
| Q2 2024 | 2 | $226k | 0 | 0 |
| Q3 2024 | 1 | $160k | 0 | 0 |
| Q4 2024 | 2 | $177k | 0 | 0 |
| Q1 2025 | 1 | $45k | 0 | 0 |
| Q2 2025 | 1 | $40k | 0 | 0 |
| Q3 2025 | 1 | $62k | 0 | 0 |
| Q4 2025 | 1 | $53k | 16 | 2 |
| Q1 2026 | 1 | $74k | 14 | 7 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CCCC and GILD →CCCC and AMGN →CCCC and ARGX →Choose a stock to compare with CCCC →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CCCC, latest filings →Back to the 13F Explorer →